Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Ximelagatran | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | Ximelagatran | hsa00310 | Lysine degradation | 2.86E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | Ximelagatran | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Ximelagatran | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Ximelagatran | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | Ximelagatran | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Ximelagatran | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Ximelagatran | hsa03040 | Spliceosome | 4.73E-02 | 6 | Q14562, O43143, P52298, Q13595, Q07955, Q13243 | DHX8, DHX15, NCBP2, TRA2A, SFRS1, SFRS5 | More | | Ximelagatran | hsa03050 | Proteasome | 3.05E-02 | 1 | P55036 | PSMD4 | More | | Ximelagatran | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Ximelagatran | hsa04015 | Rap1 signaling pathway | 2.05E-03 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | | Ximelagatran | hsa04022 | cGMP-PKG signaling pathway | 1.05E-02 | 3 | P24844, Q8WYR1, Q15746 | MYL9, PIK3R5, MYLK | More | | Ximelagatran | hsa04024 | cAMP signaling pathway | 1.40E-02 | 3 | P48058, P25116, P24844 | GRIA4, F2R, MYL9 | More | | Ximelagatran | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | | Ximelagatran | hsa04071 | Sphingolipid signaling pathway | 5.85E-03 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Ximelagatran | hsa04080 | Neuroactive ligand-receptor interaction | 2.76E-02 | 6 | Q15722, P21453, O00398, P25116, P21462, Q16581 | LTB4R, S1PR1, P2RY10, F2R, FPR1, C3AR1 | More | | Ximelagatran | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Ximelagatran | hsa04145 | Phagosome | 8.42E-03 | 6 | Q15080, P14598, Q13509, P68371, Q13488, O60603 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2 | More | | Ximelagatran | hsa04217 | Necroptosis | 2.64E-03 | 10 | P01375, P01568, P48023, Q13489, Q13546, Q14765, Q6FI13, Q99878, P10415, O43633 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, H2AC18; H2AC19, H2AC14, BCL2, CHMP2A | More | | Ximelagatran | hsa04270 | Vascular smooth muscle contraction | 4.65E-02 | 2 | Q15746, P24844 | MYLK, MYL9 | More | | Ximelagatran | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Ximelagatran | hsa04510 | Focal adhesion | 3.36E-02 | 3 | P08514, Q15746, P24844 | ITGA2B, MYLK, MYL9 | More | | Ximelagatran | hsa04512 | ECM-receptor interaction | 2.44E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Ximelagatran | hsa04514 | Cell adhesion molecules | 4.65E-02 | 2 | P16109, O00501 | SELP, CLDN5 | More | | Ximelagatran | hsa04530 | Tight junction | 7.42E-04 | 4 | Q8TEU7, O00501, Q14247, P24844 | RAPGEF6, CLDN5, CTTN, MYL9 | More | | Ximelagatran | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Ximelagatran | hsa04610 | Complement and coagulation cascades | 9.44E-04 | 4 | P25116, P00734, P0C0L4, P10909 | F2R, F2, C4A, CLU | More | | Ximelagatran | hsa04611 | Platelet activation | 7.40E-06 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Ximelagatran | hsa04612 | Antigen processing and presentation | 2.40E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Ximelagatran | hsa04613 | Neutrophil extracellular trap formation | 4.51E-03 | 16 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P68431, P14598, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Ximelagatran | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Ximelagatran | hsa04623 | Cytosolic DNA-sensing pathway | 2.86E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Ximelagatran | hsa04650 | Natural killer cell mediated cytotoxicity | 2.95E-02 | 7 | P06239, P20963, Q13241, P26718, O14931, P26717, P26715 | LCK, CD247, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | | Ximelagatran | hsa04657 | IL-17 signaling pathway | 3.91E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Ximelagatran | hsa04658 | Th1 and Th2 cell differentiation | 1.78E-04 | 11 | Q04759, P07766, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Ximelagatran | hsa04660 | T cell receptor signaling pathway | 1.44E-04 | 13 | P01375, Q9UDY8, Q04759, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Ximelagatran | hsa04666 | Fc gamma R-mediated phagocytosis | 1.88E-02 | 4 | P23528, O14494, P14598, P17252 | CFL1, PLPP1, NCF1, PRKCA | More | | Ximelagatran | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Ximelagatran | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | Ximelagatran | hsa04720 | Long-term potentiation | 5.06E-03 | 4 | P17252, Q16566, P0DP23, Q14643 | PRKCA, CAMK4, CALM1, ITPR1 | More | | Ximelagatran | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Ximelagatran | hsa04724 | Glutamatergic synapse | 2.94E-02 | 2 | P48058, Q9NSB8 | GRIA4, HOMER2 | More | | Ximelagatran | hsa04725 | Cholinergic synapse | 2.72E-03 | 5 | Q14643, P17252, P62873, Q16566, P10415 | ITPR1, PRKCA, GNB1, CAMK4, BCL2 | More | | Ximelagatran | hsa04726 | Serotonergic synapse | 4.49E-02 | 4 | Q14643, P17252, P62873, P33260 | ITPR1, PRKCA, GNB1, CYP2C18 | More | | Ximelagatran | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Ximelagatran | hsa04810 | Regulation of actin cytoskeleton | 1.38E-03 | 4 | P24844, Q15746, P08514, P25116 | MYL9, MYLK, ITGA2B, F2R | More | | Ximelagatran | hsa04912 | GnRH signaling pathway | 3.89E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Ximelagatran | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Ximelagatran | hsa04921 | Oxytocin signaling pathway | 6.37E-03 | 3 | Q15746, P24844, Q8WYR1 | MYLK, MYL9, PIK3R5 | More | | Ximelagatran | hsa04925 | Aldosterone synthesis and secretion | 1.29E-02 | 4 | Q14643, P0DP23, P17252, Q16566 | ITPR1, CALM1, PRKCA, CAMK4 | More | | Ximelagatran | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Ximelagatran | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Ximelagatran | hsa04966 | Collecting duct acid secretion | 2.86E-02 | 2 | Q13488, Q9Y666 | TCIRG1, SLC12A7 | More | | Ximelagatran | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | | Ximelagatran | hsa05020 | Prion disease | 3.99E-02 | 6 | O14521, Q14643, Q13509, P68371, P14598, Q15080 | SDHD, ITPR1, TUBB3, TUBB2C, NCF1, NCF4 | More | | Ximelagatran | hsa05022 | Pathways of neurodegeneration - multiple diseases | 4.11E-02 | 8 | Q14643, Q13509, P68371, P10415, O14521, Q13561, P17252, P0DP23 | ITPR1, TUBB3, TUBB2C, BCL2, SDHD, DCTN2, PRKCA, CALM1 | More | | Ximelagatran | hsa05130 | Pathogenic Escherichia coli infection | 2.51E-02 | 3 | Q14247, O00501, P25116 | CTTN, CLDN5, F2R | More | | Ximelagatran | hsa05132 | Salmonella infection | 1.11E-02 | 8 | Q9UJU2, Q13546, Q13489, P10415, O60603, Q13561, Q13509, P68371 | LEF1, RIPK1, BIRC3, BCL2, TLR2, DCTN2, TUBB3, TUBB2C | More | | Ximelagatran | hsa05133 | Pertussis | 2.02E-03 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Ximelagatran | hsa05140 | Leishmaniasis | 1.87E-02 | 7 | P13612, O75015, P13765, O60603, P01375, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MAPK14, NCF4 | More | | Ximelagatran | hsa05143 | African trypanosomiasis | 3.01E-03 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Ximelagatran | hsa05146 | Amoebiasis | 3.91E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Ximelagatran | hsa05152 | Tuberculosis | 4.18E-03 | 7 | Q13488, P0DP23, P48382, O60603, P10415, P01568, Q9UDY8 | TCIRG1, CALM1, RFX5, TLR2, BCL2, IFNA21, MALT1 | More | | Ximelagatran | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Ximelagatran | hsa05163 | Human cytomegalovirus infection | 4.73E-02 | 6 | P62873, Q14643, P0DP23, P17252, Q13546, P01568 | GNB1, ITPR1, CALM1, PRKCA, RIPK1, IFNA21 | More | | Ximelagatran | hsa05170 | Human immunodeficiency virus 1 infection | 1.16E-03 | 10 | P62873, P0DP23, P17252, Q13546, Q14643, P01568, O60603, P23528, P10415, Q9Y6Q5 | GNB1, CALM1, PRKCA, RIPK1, ITPR1, IFNA21, TLR2, CFL1, BCL2, AP1M2 | More | | Ximelagatran | hsa05202 | Transcriptional misregulation in cancer | 3.00E-02 | 13 | P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Ximelagatran | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | | Ximelagatran | hsa05310 | Asthma | 1.25E-03 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | Ximelagatran | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Ximelagatran | hsa05321 | Inflammatory bowel disease | 3.16E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Ximelagatran | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | | Ximelagatran | hsa05332 | Graft-versus-host disease | 4.38E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Ximelagatran | hsa05340 | Primary immunodeficiency | 3.73E-02 | 2 | P11912, P16871 | CD79A, IL7R | More | | Ximelagatran | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | Ximelagatran | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | |